Condition: Rectal Cancer Patients · Sponsor: University Hospital Ostrava
This prospective, multi-centre, randomised clinical trial aims to compare the effect of neoadjuvant chemoradiotherapy versus primary surgery on circulating tumor cells (CTCs) in patients with stage II-III rectal cancer without circumferential resection mar-gin involvement. CTCs are considered a promising biomarker for disease dissemination and treatment response. Patients will be randomized to either primary surgical resection with total mesorectal excision or long-course neoadjuvant chemoradiotherapy followed by surgery. Serial blood samples will be collected at predefined time points to assess the presence and dynamics of CTCs. Secondary endpoints include perioperative morbidity and mortality, local recurrence rate, disease-free survival, and overall survival. The results of this study may provide new insights into the prognostic role of CTCs and contribute to optimising treatment strategies for rectal cancer.
This description comes directly from the study's public registry record.
Jiří Hynčica · 0042059737 · jiri.hyncica@fno.cz
Always discuss trial participation with your own doctor first.
| University Hospital Olomouc | Olomouc, Czechia | Recruiting |
| Palacky University Olomouc, Faculty of Medicine | Olomouc, Czechia | Recruiting |
| University Hospital Ostrava | Ostrava, Czechia | Recruiting |
| Municipal Hospital Ostrava - Fifejdy | Ostrava, Czechia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07194616